| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Paul A. Grayson is Director at SKYE. Paul A. Grayson's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $317K at current prices.
The SKYE filings lean toward selling, a net 86,551 shares.
Paul A. Grayson has 8 Form 4 filings on record from August 2023 to March 2026, all as Director at Skye Bioscience (SKYE), 2023–2026.
The 10 reported transactions were 5 option or other derivative awards, 3 stock awards and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $432K.
The only open-market sale was 86,551 shares of SKYE at an average $4.99 on November 18, 2024, about $432K. Twelve months later SKYE was down 71%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2024 | SKYE Skye Bioscience, Inc. | Director | Sell | 86,551 | $4.99 | $432,061.41 | -25.0% | -31.8% | -70.8% |